Citadel Advisors
LEGN icon

Citadel Advisors’s Legend Biotech LEGN Stock Holding History

Citadel Advisors’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$986K Sell
34,141
-482,839
-93% -$13M ﹤0.01% 8230
2026
Q1 		$9.35M Buy
516,980
+338,940
+190% +$6.46M ﹤0.01% 3351
2025
Q4 		$3.87M Sell
178,040
-204,772
-53% -$5.87M ﹤0.01% 4720
2025
Q3 		$12.5M Buy
382,812
+217,751
+132% +$8.04M ﹤0.01% 2935
2025
Q2 		$5.86M Buy
165,061
+9,887
+6% +$320K ﹤0.01% 3842
2025
Q1 		$5.27M Sell
155,174
-2,749,683
-95% -$98.6M ﹤0.01% 3780
2024
Q4 		$94.5M Buy
2,904,857
+1,588,303
+121% +$65.8M 0.02% 768
2024
Q3 		$64.2M Sell
1,316,554
-128,309
-9% -$6.83M 0.01% 1008
2024
Q2 		$64M Buy
1,444,863
+300,387
+26% +$13.9M 0.01% 959
2024
Q1 		$64.2M Buy
1,144,476
+978,545
+590% +$59M 0.01% 1025
2023
Q4 		$9.98M Buy
165,931
+144,476
+673% +$9.16M ﹤0.01% 2846
2023
Q3 		$1.44M Sell
21,455
-17,357
-45% -$1.21M ﹤0.01% 5844
2023
Q2 		$2.68M Buy
38,812
+31,511
+432% +$2.06M ﹤0.01% 4652
2023
Q1 		$352K Sell
7,301
-24,192
-77% -$1.18M ﹤0.01% 9035
2022
Q4 		$1.57M Sell
31,493
-226,783
-88% -$11M ﹤0.01% 5940
2022
Q3 		$10.5M Buy
258,276
+137,467
+114% +$6.45M ﹤0.01% 2686
2022
Q2 		$6.64M Buy
120,809
+44,044
+57% +$1.86M ﹤0.01% 3296
2022
Q1 		$2.79M Buy
76,765
+53,585
+231% +$2.12M ﹤0.01% 5364
2021
Q4 		$1.08M Sell
23,180
-140,745
-86% -$7.14M ﹤0.01% 7758
2021
Q3 		$8.29M Buy
163,925
+107,964
+193% +$4.49M ﹤0.01% 3395
2021
Q2 		$2.3M Sell
55,961
-540,753
-91% -$18.4M ﹤0.01% 6250
2021
Q1 		$17.3M Buy
596,714
+360,065
+152% +$9.82M ﹤0.01% 2154
2020
Q4 		$6.66M Sell
236,649
-68,527
-22% -$1.97M ﹤0.01% 3200
2020
Q3 		$9.42M Buy
305,176
+274,817
+905% +$9.25M ﹤0.01% 2356
2020
Q2 		$1.29M Buy
+30,359
New +$1.19M ﹤0.01% 5355

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Citadel Advisors's LEGN Position: Q2 2026 in Review

Citadel Advisors reduced its Legend Biotech (LEGN) stake by 93% in Q2 2026, selling an estimated $13M and leaving 34,141 shares worth $986K. The position accounts for ﹤0.01% of the portfolio, ranked #8230.

Citadel Advisors first reported a position in LEGN in Q2 2020 and has held it in 25 quarters since. The position peaked at $94.5M in Q4 2024. 218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Citadel Advisors held 34,141 shares of Legend Biotech worth $986K as of Q2 2026.
  • Citadel Advisors sold 482,839 Legend Biotech shares in Q2 2026, an estimated $13M.
  • Legend Biotech made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8230 holding.
  • Citadel Advisors first reported a position in Legend Biotech in Q2 2020 and has held it in 25 quarters since.
  • Citadel Advisors's Legend Biotech position peaked at $94.5M in Q4 2024.
  • 218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.